PLUS1
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Miragen Therapeutics Inc | MGEN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.03853 | -4.45% | 0.827469 | 0.8574 | 0.785 | 0.85 | 0.866 | 20:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.79 | 1.10 | 0.31 | 28.18% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 188 | 53,158 | $ 0.8176543 | $ 43,465 | 192,289 | 0.6501 - 6.5999 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 5 | $ 0.82 | USD |
Miragen Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 25.69M | 31.05M | $ -32.70M | -1.09 | - | 29.83M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 7.00 | 3.90% |
Miragen Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 10/16/2019 | 08:30 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 8/23/2019 | 18:17 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 8/15/2019 | 08:00 | GlobeNewswire Inc. | miRagen Therapeutics to Present a Corporate Overview at the.. |
| 8/12/2019 | 08:00 | GlobeNewswire Inc. | miRagen Therapeutics to Present a Corporate Overview at the.. |
| 8/08/2019 | 06:04 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 8/07/2019 | 16:01 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 7/24/2019 | 08:00 | GlobeNewswire Inc. | Miragen Therapeutics to Report Second Quarter 2019 Financial.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MGEN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.99 | 1.39 | 0.785 | 0.9430138 | 435,891 | -0.16253 | -16.42% |
| 1 Month | 0.8515 | 1.39 | 0.6501 | 0.8542267 | 183,008 | -0.02403 | -2.82% |
| 3 Months | 2.03 | 2.14 | 0.6501 | 1.13 | 259,284 | -1.20 | -59.24% |
| 6 Months | 2.73 | 3.65 | 0.6501 | 1.65 | 194,972 | -1.90 | -69.69% |
| 1 Year | 4.54 | 6.5999 | 0.6501 | 2.40 | 202,523 | -3.71 | -81.77% |
| 3 Years | 11.11 | 18.00 | 0.6501 | 5.21 | 161,630 | -10.28 | -92.55% |
| 5 Years | 11.11 | 18.00 | 0.6501 | 5.21 | 161,630 | -10.28 | -92.55% |
Miragen Therapeutics Description
| Miragen Therapeutics Inc is a US-based clinical-stage biopharmaceutical company discovering and developing proprietary RNA (Ribonucleic acid)-targeted therapeutics. The company's main product candidates, MRG-106, MRG-201, MRG-107, and MRG-110. MRG-106 and MRG-201 are currently in Phase 1 clinical trials. The company mainly focuses on developing such therapeutics which will target blood cancers, pathological fibrosis, and revascularization. |
